Premium
IC‐P‐039: ASSOCIATION OF ANTICHOLINERGIC MEDICATION USE WITH IN VIVO ALZHEIMER'S DISEASE PATHOLOGIES
Author(s) -
Lee Jun Ho,
Byun Min Soo,
Yi Dahyun,
Jeon So Yeon,
Jung Gijung,
Lee Han Na,
Sohn Bo Kyung,
Lee Jun-Young,
Ryu Seung-Ho,
Lee Dong Woo,
Lee Dong Young
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.4201
Subject(s) - pittsburgh compound b , dementia , medicine , clinical dementia rating , neuroimaging , alzheimer's disease , cognitive decline , standardized uptake value , alzheimer's disease neuroimaging initiative , positron emission tomography , disease , psychiatry , nuclear medicine
the pre-dementia stage (LOMCI>EOMCI). EOAD had greater GM-FW increases in the parietal/precuneus and middle-temporal regions than LOAD (Fig. 3). Lastly, parietal GM-FW increases contributed to global cognitive impairment in MCI while parietal and temporalWM abnormalities and GM thinning related to lower MoCA in dementia (Table 1). Conclusions: Our study revealed differential patterns of GM and WM macro/microstructural changes in earlyand late-onset AD and MCI. Findings suggested that GM microstructural changes appeared earlier than cortical thinning and were better associated with cognitive decline. The combined WM and GM microstructural assays could help differential diagnosis and early detection in preclinical and prodromal stages of neurodegeneration. rday, July 13, 2019